---ADDS SHARE PRICE & BROKER COMMENT---
For it is giving no fewer than six presentations on the company's ImmunoBody and Moditope immunotherapy platforms.
Immunotherapy is an emerging and exciting form of science that uses the body’s own immune system to battle diseases such as cancer.
The presentations will share with the specialist audience the advances being made with its lead treatment SCIB1 for hard-to-treat cases of melanoma and SCIB2 for lung cancer as well as other developments from the two platforms.
Scancell joint chief-executive, Lindy Durrant, who is also professor of cancer immunotherapy at Nottingham University, said: "Scancell's presentations at this important conference exemplify the growing body of exciting data emerging from both our SCIB1 clinical trial and our ImmunoBody,and Moditope, immunotherapy technology platforms, and provide a solid foundation for building a broad immuno-oncology franchise in the future.”
The shares marked time at 23.2p in afternoon trade, valuing the business at £52mln. Panmure Gordon analyst Dr Mike Mitchell reckons the stock is worth 79p.
Of today’s update, he said: “Conference presentations are an important element of the communication of scientific advances and in our view it is notable that six will be delivered at the same event.
“The presentations exemplify the growing body of data that is emerging from Scancell’s technology platforms, reflecting their potential in delivering effective and complimentary immunotherapies to treat a range of cancers.”